{"id":"W2255445538","doi":"10.1007/s11938-016-0085-z","title":"Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review","year":2016,"lang":"en","type":"article","venue":"Current Treatment Options in Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"AbbVie Canada; National Institutes of Health; Ironwood Pharmaceuticals, Incorporated","keywords":"Medicine; Inflammatory bowel disease; Ulcerative colitis; Drug; Dosing; Therapeutic drug monitoring; Antibody; Disease; Clinical trial; Monoclonal antibody; Crohn's disease; Vedolizumab; Immunology; Trough level; Efficacy; Tumor necrosis factor alpha; Internal medicine; Pharmacology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001987039,0.0007259878,0.002382369,0.002357555,0.0002242989,0.001981689,0.0008516841,0.001200755,0.002981611],"category_scores_gemma":[0.003334992,0.0002822821,0.0009723429,0.001971134,0.0006090277,0.002034725,0.0009254916,0.00192402,0.001313117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008047574,"about_ca_system_score_gemma":0.001552774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007251042,"about_ca_topic_score_gemma":0.001352707,"domain_scores_codex":[0.999243,0.0001797104,0.0001727151,0.0001102239,0.0002370253,0.00005730895],"domain_scores_gemma":[0.997242,0.001584617,0.0005346509,0.0000512591,0.0004798223,0.0001077642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003413132,0.00007154304,0.0008731274,0.00947968,0.0001612608,0.0001996939,0.00004196343,0.0002510531,0.001419157,0.002094498,0.0120007,0.9730661],"study_design_scores_gemma":[0.0001759904,0.0007197004,0.00504388,0.01189962,0.001416869,0.003667907,0.0001909549,0.0007762071,0.003267857,0.004609334,0.9681364,0.00009510636],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000190537,0.9983079,0.0002848531,0.0005425087,0.0001558818,0.000004868252,0.00001940214,0.000009051853,0.0004849523],"genre_scores_gemma":[0.003521394,0.993877,0.0008685691,0.0007168775,0.0006219116,0.00001106071,0.00005703893,0.000004526423,0.0003217005],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002981611,"threshold_uncertainty_score":0.0105086,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01589544296324558,"score_gpt":0.3056780486312765,"score_spread":0.2897826056680309,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}